Some patients dropped out of the trial early because they had lost so much weight.

By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

By Maggie Fick LONDON, Dec 11 (Reuters) - Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much weight loss comes with risks.

Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related ...

This is no reason to panic.

A next-generation obesity shot from Eli Lilly & Co. helped patients lose almost a quarter of their body weight, potentially ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

A recent study points to a potential link between GLP-1 drugs and its ability to reduce risk of epilepsy in people with type 2 diabetes. GLP-1 drugs (semaglutide) are those which mimic the function of ...

News and commentary from the endocrinology world ...

Roche (RHHBY) is upgraded to Buy as strong 2025 growth, new drug launches, and obesity drug potential create an attractive investment.